缬沙坦联合活性维生素D治疗IgA肾病蛋白尿的安全性与疗效观察

目的探讨缬沙坦联合活性维生素D治疗IgA肾病蛋白尿的疗效及不良反应。方法将某医院收治的128例lgA肾病蛋白尿患者作为研究对象,依照随机分配原则,分为治疗组和对照组,每组各64例,治疗组使用缬沙坦联合活性维生素D治疗,对照组单用活性维生素D,两组疗程均为两个月,观察记录治疗前后患者尿蛋白量及药物不良反应的情况。结果治疗组与对照组相比较,治疗组总有效率显著高于对照组(P0.01),治疗组24h蛋白尿改善情况显著优于对照组(P0.05),且两组患者均未出现严重不良反应。结论缬沙坦联合活性维生素D治疗lgA肾病疗效显著,能够显著降低患者尿蛋白,且临床安全性较好。

Observation on the safety and efficacy of valsartan combined with active vitamin D for proteinuria in IgA nephropathy

Objective To investigate the curative effects and adverse reactions of valsartan combined with active vitamin D for proteinuria in IgA nephropathy. Methods 128 cases of IgA nephrotie proteinuria treated in a hospital were selected and divided into treatment group and control group, 64 cases for each group. Treatment group received valsartan combined with active vitamin D, while control group received active vitamin D alone. Both groups were treated for 2 months and ob- served for the quantity of urine protein and adverse drug reactions before and after treatment. Results The total effective rate was significantly higher in treatment group than in control group （ P 〈 0.01 ）, and the 24h urine protein quantity was also improved significantly in treatment group than in control group （ P 〈 0.05 ）, and both groups had no serious adverse reactions. Conclusions Valsartan combined with active vitamin D is obviously effective for IgA nephropathy, and can significantly reduce the quantity of urine protein, moreover, it is of better clinical safety.